Other animal experiments demonstrated that the introduction of CSF-1R inhibitors after anti-VEGF drug resistance reduced the tumor size to little or no measurable degree in high-grade serous ovarian cancer [120]. The gene discussed is VEGFA; the disease is neoplasm.